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fute the claim that price increases do not reduce 
patients’ access to these medications. Decreasing 
demand also indicates a correcting market re-
sponse to increased prices that may be a valuable 
restraining force to pharmaceutical price increases.
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Novel Treatments for Airway Disease
To the Editor: The study by Cahill et al. (May 18 
issue)1 shows reductions in airway hyperrespon-
siveness, mast-cell counts, and tryptase release 
after treatment with imatinib, a KIT inhibitor, in 
62 patients with severe refractory asthma. Tar-
geting mast cells with KIT inhibitors is indeed 
an appealing, innovative approach for severe 
asthma. We have previously investigated another 
KIT inhibitor, masitinib, in 44 patients with 
 severe glucocorticoid-dependent asthma.2 At 16 
weeks of treatment, a similar reduction in oral 
glucocorticoids was observed with masitinib and 
placebo. However, the Asthma Control Question-
naire score showed significantly better control in 
the masitinib group than in the placebo group. 
Furthermore, a bronchial epithelial KIT-positive 
subpopulation exists and is increased in asthma.3 
We thus propose that KIT inhibitors may target 
Variable 2012 2013 2014 2015 P Value
No. of inpatients
Total 1,435,440 1,452,723 1,437,824 1,470,007 —
Per hospital 30,541±12,542 30,909±12,702 30,592±12,685 31,277±12,797 0.06
No. of patients receiving nitroprusside
Total 17,242 16,761 13,304 8,159 —
Per 1000 inpatients per hospital 9.30±13.41 9.11±12.19 7.71±9.49 4.99±5.13 <0.001
No. of patients receiving nitroglycerin
Total 21,778 26,465 40,140 47,377 —
Per 1000 inpatients per hospital 16.17±16.53 18.99±14.29 27.70±15.87 30.55±25.76 <0.001
No. of patients receiving isoproterenol
Total 4,079 4,058 3,335 2,650 —
Per 1000 inpatients per hospital 2.76±2.31 2.66±2.48 2.17±1.90 1.65±1.29 <0.001
No. of patients receiving dobutamine
Total 11,762 11,848 12,180 12,552 —
Per 1000 inpatients per hospital 8.02±5.14 7.96±5.36 8.24±5.77 8.31±5.65 0.74
*  Plus–minus values are means ±SD.
Table 1. Changes in the Utilization of Nitroprusside and Isoproterenol, as Compared with Nitroglycerin and Dobutamine, in 47 U.S. Hospitals 
from 2012 to 2015.*
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various cell types besides mast cells in asthma, 
including bronchial epithelial cells.
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To the Editor: Imatinib mesylate is used as a 
treatment for chronic myeloid leukemia and gas-
trointestinal stromal tumors.1 A better clinical 
benefit and improved responses in these tumors2,3 
are associated with therapeutic plasma levels of 
imatinib. The article by Cahill and colleagues ex-
amining the effect of imatinib treatment on air-
way responsiveness in patients with severe re-
fractory asthma has shown proof of the principle 
that imatinib may have therapeutic benefit in 
asthma. Because imatinib clearance may be in-
creased after chronic exposure over a period of 
12 months,4 we wondered whether Cahill et al. 
have samples to assess plasma levels of imatinib 
to determine whether there is a relationship be-
tween such levels and therapeutic effects.
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To the Editor: Wechsler et al. (May 18 issue)1 
report on the use of mepolizumab in eosinophil-
ic granulomatosis with polyangiitis.1 In the same 
issue, Cahill et al. report on the use of imatinib 
in refractory asthma. Imatinib is already well ac-
cepted as a treatment for FIP1L1-PDGFRA fusion–
associated myeloproliferative hypereosinophilic 
syndrome, but there are only two reports of its 
use in eosinophilic granulomatosis with polyangi-
itis.2,3 Since April 2016, I have been treating a 
patient with severe, biopsy-proven, FIP1L1-PDGFRA–
negative, JAK2-negative eosinophilic granuloma-
tosis with polyangiitis. After a lack of response 
to cyclophosphamide, intravenous immune glob-
ulin, rituximab, and reslizumab, the patient’s 
disease remained active during high-dose gluco-
corticoid treatment. I then began imatinib. With-
in days, the patient’s C-reactive protein level had 
almost normalized, and he has since been 
weaned down to 2 mg of prednisone a day.
This is just a single case, and yet for our 
thinking on the pathogenesis and management 
of eosinophilic granulomatosis with polyangiitis, 
it may be important. Our clear success, coupled 
with the failure of multiple known medications 
for the disorder, suggests that further research 
into the roles of the various imatinib-sensitive 
tyrosine kinases in eosinophilic granulomatosis 
with polyangiitis is in order.
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To the Editor: Wechsler et al. report that ap-
proximately half the patients with relapsing or 
refractory eosinophilic granulomatosis with poly-
angiitis had protocol-defined remission after 
mepolizumab therapy. The benefit of treatment 
was slightly greater with respect to asthma re-
lapses and sinonasal relapses than with respect 
to vasculitis relapses. We wonder whether there 
was a relationship among the blood eosinophil 
count, the number of asthma exacerbations in 
the previous year, and the response to mepoliz-
umab, as is the case for severe eosinophilic asth-
ma.1 It is conceivable that mepolizumab may be 
particularly useful for patients who, according to 
the recently suggested revised nomenclature for 
eosinophilic granulomatosis with polyangiitis,2 
fulfill the criteria for hypereosinophilic asthma 
with systemic (nonvasculitic) manifestations.
Giovanni Rolla, M.D. 
Luisa Brussino, M.D.
University of Turin 
Turin, Italy 
grolla@ mauriziano . it
No potential conflict of interest relevant to this letter was re-
ported.
1. Yancey SW, Ortega HG, Keene ON, et al. Meta-analysis of 
asthma-related hospitalization in mepolizumab studies of se-
vere eosinophilic asthma. J Allergy Clin Immunol 2017; 139(4): 
1167-1175.e2.
2. Cottin V, Bel E, Bottero P, et al. Revisiting the systemic vas-
culitis in eosinophilic granulomatosis with polyangiitis (Churg-
Strauss): a study of 157 patients by the Groupe d’Etudes et de 
Recherche sur les Maladies Orphelines Pulmonaires and the 
European Respiratory Society Taskforce on eosinophilic granu-
lomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev 
2017; 16: 1-9.
DOI: 10.1056/NEJMc1708004
Dr. Cahill and colleagues reply: In our study, 
we found that treatment with imatinib reduced 
serum levels of mast-cell tryptase, decreased air-
way hyperresponsiveness, and improved airway 
function. Several of these improvements corre-
lated with indexes of reduced mast-cell burden 
or function. As stated in our article, we recog-
nize that KIT is expressed on cells other than 
mast cells. Thus, we agree with Martinez-Anton 
and colleagues that it is possible that the effects 
we observed could reflect additional effects of 
imatinib that are unrelated to mast cells. Nonethe-
less, the observation that changes in airway func-
tion correlated with changes in airway tryptase-
positive cells suggests that the salutary effect was 
related to the effect on mast cells.
Regarding the query by Hammoudi and col-
leagues about whether plasma levels of imatinib 
might affect efficacy: we did not undertake such 
measurement. We did assess for an association 
between participant body weight, which has been 
suggested to influence plasma levels of ima-
tinib,1 and our primary clinical outcome, change 
in airway hyperresponsiveness, and did not ob-
serve an association.
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Dr. Wechsler and colleagues reply: We per-
formed post hoc modeling to explore the rela-
tionship between various baseline characteristics 
and treatment effect. The modeling work provided 
some evidence of an association between higher 
baseline blood eosinophil counts and benefits of 
mepolizumab; however, caution is required in 
concluding a direct causal relationship because 
of the strong association between low baseline 
blood eosinophil counts and a high oral gluco-
corticoid dose at baseline. A high oral glucocor-
ticoid dose at baseline was a confounding vari-
able for several clinical end points owing to the 
need to slowly taper oral glucocorticoids and the 
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increased difficulty of achieving a greater per-
cent reduction in the average daily dose when 
starting with a higher dose at baseline. No inter-
action was seen between the number of relapses 
during the previous 2 years and treatment effect. 
Overall, the results of the modeling were incon-
sistent among end points in terms of the strength 
of the evidence, and caution is needed in conclud-
ing any causal relationship between the factors 
that were evaluated and treatment effect.
Although approved only for eosinophilic asth-
ma,1,2 mepolizumab has now shown efficacy in 
eosinophilic granulomatosis with polyangiitis and 
idiopathic hypereosinophilic syndrome.3 With its 
interleukin-5–blocking mechanism of action, it 
is likely that this therapy will have beneficial 
effects in other hypereosinophilic conditions, 
especially in intermediate phenotypes including 
the recently proposed entity of hypereosino-
philic asthma with nonvasculitic systemic mani-
festations.
As with the patients in our study who did not 
have a response to mepolizumab, Kedar’s case 
report of a patient who had a response to ima-
tinib therapy after not having a response to other 
therapies, including reslizumab, highlights the 
need to do further studies to better understand 
the underlying pathobiologic mechanisms of 
eosinophilic granulomatosis with polyangiitis. 
Although the eosinophil appears to be the 
dominant cell implicated in most patients with 
eosinophilic granulomatosis with polyangiitis, it 
appears that this is a complex syndrome with 
several putative causative elements that make it 
difficult to differentiate from other hypereosino-
philic syndromes. Given the apparent benefit of 
imatinib in Kedar’s patient, we agree that future 
research exploring the role of tyrosine kinase 
inhibition in eosinophilic granulomatosis with 
polyangiitis is warranted.
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Exercise Type in Dieting Obese Older Adults
To the Editor: In a well-performed clinical trial, 
Villareal et al. (May 18 issue)1 found that weight 
loss plus physical activity improved functional 
status in obese older adults. Nevertheless, conclu-
sions should be drawn with caution, because there 
was no weight-loss control group. We cannot dif-
ferentiate whether the improvement in function-
al status was caused by weight loss, physical activ-
ity, or both. We are asked to assume that the 
observed increases in physical performance, peak 
oxygen consumption, and strength are attribut-
able to increased physical activity, whereas the ob-
served decreases in body weight, lean mass, and 
bone mineral density at the hip are attributable 
to the reduced-calorie diet. If these assump-
tions are correct, we would then have to con-
clude that it could be harmful to recommend 
weight loss by means of calorie restriction. In-
deed, the “obesity paradox,”2 observations of 
lower mortality among obese older adults than 
among older adults of normal weight, raises fur-
ther questions about aiming for weight loss as an 
intervention of choice. We suggest a follow-up 
study with two comparison groups: one group 
consuming a calorie-restricted diet and another 
consuming a healthy diet (e.g., a Mediterranean 
diet3 or the DASH [Dietary Approaches to Stop 
Hypertension] diet4) that does not include calorie 
restriction.
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